Market Cap (In USD)
6.38 Billion
Revenue (In USD)
-
Net Income (In USD)
-373.63 Million
Avg. Volume
274.56 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 168.25-368.29
- PE
- -
- EPS
- -
- Beta Value
- -0.469
- ISIN
- US5588681057
- CUSIP
- 558868105
- CIK
- 1157601
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. William J. Sibold
- Employee Count
- -
- Website
- https://www.madrigalpharma.com
- Ipo Date
- 2007-02-06
- Details
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
More Stocks
-
EXAE
-
ENXEuronext N.V.
ENX
-
ARKR
-
MRCRMoro Corporation
MRCR
-
OSWALGREENOswal Greentech Limited
OSWALGREEN
-
DHARMAJDharmaj Crop Guard Limited
DHARMAJ
-
000926
-
0IZM